Will Aphria Inc (APHA) Outperform the Healthcare Sector?

Wednesday, August 12, 2020 3:25 PM | InvestorsObserver Analysts

Aphria Inc (APHA) is around the middle of the Healthcare sector according to InvestorsObserver.

APHA received an overall rating of 47, which means that it scores higher than 47% of stocks. Additionally, Aphria Inc scored a 52 in the Healthcare sector, ranking it higher than 52% of stocks in that sector.

Overall Score - 47
APHA has an Overall Score of 47. Find out what this means to you and get the rest of the rankings on APHA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Aphria Inc Stock Today?

Aphria Inc (APHA) stock is trading at $4.50 as of 3:22 PM on Wednesday, Aug 12, a gain of $0.05, or 1.17% from the previous closing price of $4.45. The stock has traded between $4.40 and $4.54 so far today. Volume today is less active than usual. So far 3,311,911 shares have traded compared to average volume of 7,482,551 shares.

To screen for more stocks like APHA click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Is Global Cord Blood Corp (CO) Stock a Great Value?

Denali Therapeutics Inc (DNLI) Stock Climbs 10.58% This Week; Should You Buy?

Should Replimune Group Inc (REPL) Stock be in Your Portfolio?

Should You Buy AcelRx Pharmaceuticals Inc (ACRX) Stock?

Sector Update: Health Care Stocks Slipping in Late Trade

Related Companies